MDM2 - Master regulator of the p53 tumor suppressor protein

Gene

Volumn 242, Issue 1-2, 2000, Pages 15-29

  Momand, Jamil ^a   Wu, Hsiao Huei ^a,b   Dasgupta, Gargi ^a,c  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Cell cycle; Checkpoint; E2F1; Gene amplification; Oncogene; p73; Rb; Transactivator; Ubiquitin ligase

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; UBIQUITIN;

APOPTOSIS; CELL CYCLE; CONSENSUS SEQUENCE; FISH; FROG; GENE ACTIVATION; GENE AMPLIFICATION; GENE SEQUENCE; HAMSTER; HUMAN; MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RAT; REVIEW; SPECIES; TUMOR; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEIN P53;

ANURA; CRICETINAE;

EID: 0033959744     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(99)00487-4     Document Type: Review

References (134)

1. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1997;1175-1184.
2. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
3. Barak Y., Oren M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 11:1992;2115-2121.
4. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461-468.
5. Barak Y., Gottlieb E., Juven-Gershon T., Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8:1994;1739-1749.
6. Blattner C., Sparks A., Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 19:1999;3704-3713.
7. Blaydes J.P., Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene. 16:1998;3317-3322.
8. Blaydes J.P., Gire V., Rowson J.M., Wynford-Thomas D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene. 14:1997;1859-1868.
9. Blommers M.J.J., Fendrich G., Garciaecheverria C., Chene P. On the interaction between p53 and mdm2-transfer NOE study of a p53-derived peptide ligated to mdm2. J. Am. Chem. Soc. 119:1997;3425-3426.
10. Boddy M.N., Freemont P.S., Borden K.L. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem. Sci. 19:1994;198-199.
11. Böttger A., Böttger V., Sparks A., Liu W.-L., Howard S.F., Lane D.P. Design of a synthetic Mdm-2 binding protein that activates the p53 response in vivo. Curr. Biol. 7:1997;860-869.
12. Botuyan M.V., Momand J., Chen Y. Solution conformation of an essential region of the p53 transactivation domain. Folding Design. 2:1997;331-342.
13. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
14. Cahilly-Snyder L., Yang-Feng T., Francke U., George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13:1987;235-244.
15. Chen C.Y., Oliner J.D., Zhan Q., Fornace A.J.J., Vogelstein B., Kastan M.B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA. 91:1994;2684-2688.
16. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:1993;4107-4114.
17. Chen L., Marechal V., Moreau J., Levine A.J., Chen J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J. Biol. Chem. 272:1997;22 966-22 973.
18. Chen L., Agrawal S., Zhou W., Zhang R., Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA. 85:1998;195-200.
19. Chin L., Pomerantz J., DePinho R.A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci. 23:1998;291-296.
20. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
21. Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A.M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 265:1994;386-391. Published erratum appears in Science. 267:1995;1515.
22. Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A.M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 265:1994;386-391. Published erratum appears in Science. 267:1995;1515.
23. de Stanchina E., McCurrach M.E., Zindy F., Shieh S.Y., Ferbeyre G., Samuelson A.V., Prives C., Roussel M.F., Sherr C.J., Lowe S.W. E1A signaling to p53 involves the p19 (ARF) tumor suppressor. Genes Dev. 12:1998;2434-2442.
24. Di Leonardo A., Linke S.P., Clarkin K., Wahl G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
25. Dobbelstein M., Wienzek S., König C., Roth J. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene. 18:1999;2101-2106.
26. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A.J., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221.
27. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1:1992;45-49.
28. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
29. Elenbaas B., Dobbelstein M., Roth J., Shenk T., Levine A.J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2:1996;439-451.
30. Erhardt P., Tomaselli K.J., Cooper G.M. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J. Biol. Chem. 272:1997;15 049-15 052.
31. Fakharzadeh S.S., Trusko S.P., George D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1991;1565-1569.
32. Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
33. Flatt P.M., Price J.O., Shaw A., Pientenpol J.A. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. Cell Growth Differ. 9:1998;535-543.
34. Ford J.M., Hanawalt P.C. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem. 272:1997;28 073-28 080.
35. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
36. Freedman D.A., Wu L., Levine A.J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55:1999;96-107.
37. Friedman P.N., Chen X., Bargonetti J., Prives C. The p53 protein is an unusually shaped tetramer the binds directly to DNA. Proc. Natl. Acad. Sci. USA. 90:1993;3319-3323.
38. Fu L., Minden M.D., Benchimol S. Translational regulation of human p53 gene expression. EMBO J. 15:1996;4392-4401.
39. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:1998;2973-2983.
40. Gottlieb E., Haffner R., King A., Asher G., Gruss P., Lonai P., Oren M. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J. 16:1997;1381-1390.
41. Grossman S.R., Perez M., Kung A.L., Joseph M., Mansur C., Xiao Z.X., Kumar S., Howley P.M., Livingston D.M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell. 2:1998;405-415.
42. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
43. Haines D.S. The mdm2 proto-oncogene. Leuk. Lymphoma. 26:1997;227-238.
44. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell. 75:1993;805-816.
45. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
46. Haupt Y., Rowan S., Shaulian E., Kazaz A., Vousden K., Oren M. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia. 11:(suppl. 3):1997;337-339.
47. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
48. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18:1999;22-27.
49. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
50. Hsieh J.-K., Chan F.S.G., O'Connor D.J., Mittnacht S., Zhong S., Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell. 3:1999;181-193.
51. Hupp T.R., Meek D.W., Midgley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
52. Jeffrey P.D., Gorina S., Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
53. Jenkins J.R., Rudge K., Chumakov P., Currie G.A. The cellular oncogene p53 can be activated by mutagenesis. Nature. 317:1985;816-818.
54. Jimenez G.S., Bryntesson F., Torres-Arzayus M.I., Priestley A., Beeche M., Saito S., Sakaguchi K., Appella E., Jeggo P.A., Taccioli G.E., Wahl G.M., Hubank M. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature. 400:1999;81-83.
55. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 378:1995;206-208.
56. Jones S.N., Sands A.T., Hancock A.R., Vogel H., Donehower L.A., Linke S.P., Wahl G.M., Bradley A. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc. Natl. Acad. Sci. USA. 93:1996;14 106-14 111.
57. Jost C.A., Marin M.C., Kaelin W.G.J. p73 is a human p53-related protein that can induce apoptosis. Nature. 389:1997;191-194.
58. Juven-Gershon T., Oren M. Mdm2: the ups and downs. Mol. Med. 5:1999;71-83.
59. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A., Minty A., Chalon P., Lelias J.M., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
60. ARF. Cell. 91:1997;649-659.
61. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
62. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
63. Koshravi R., Maya R., Gottlieb T., Oren M., Shiloh Y., Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA. 2000;. in press.
64. Komarova E.A., Chernov M.V., Franks R., Wang K., Armin G., Zelnick C.R., Chin D.M., Bacus S.S., Stark G.R., Gudkov A.V. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16:1997;1391-1400.
65. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
66. Kubbutat M.H.G., Ludwig R.L., Ashcroft L.M., Vousden K.H. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18:1998;5690-5698.
67. Kubbatat M.H.G., Ludwig R.L., Levine A.J., Vousden K.H. Analysis of the degradation function of Mdm2. Cell Growth Differ. 10:1999;87-92.
68. ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. Oncogene. 18:1999;2718-2727.
69. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:1996;948-953.
70. Lai Z., Freedman D.A., Levine A.J., McLendon G.L. Metal and RNA binding proerties of the hdm2 RING finger domain. Biochemistry. 37:1998;17 005-17 015.
71. Laín S., Midgley C., Sparks A., Lane E.B., Lane D.P. An inhibitor of nuclear export actvates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with PODs. Exp. Cell Res. 248:1999;457-472.
72. Lane D.P., Hall P.A. MDM2-arbiter of p53's destruction. Trends Biol. Sci. 22:1997;372-374.
73. Lee S., Elenbaas B., Levine A., Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell. 81:1995;1013-1020.
74. Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Strut. Biol. 1:1994;877-890. Published erratum appears in Nat. Struct. Biol. 2:1995;81.
75. Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Strut. Biol. 1:1994;877-890. Published erratum appears in Nat. Struct. Biol. 2:1995;81.
76. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
77. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:1997;823-827.
78. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
79. Lu X., Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 75:1993;765-778.
80. Lundgren K., Montes de Oca Luna R., McNeill Y.B., Emerick E.P., Spencer B., Barfield C.R., Lozano G., Rosenberg M.P., Finlay C.A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11:1997;714-725.
81. Ma J., Ptashne M. A new class of yeast transcriptional activators. Cell. 51:1987;113-119.
82. Maki C.G. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J. Biol. Chem. 274:1999;16 531-16 535.
83. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:1996;2649-2654.
84. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1984;1689-1694.
85. Marechal V., Elenbaas B., Taneyhill L., Piette J., Mechali M., Nicolas J.C., Levine A.J., Moreau J. Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis. Oncogene. 14:1997;1427-1433.
86. Marston N.J., Jenkins J.R., Vousden K.H. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene. 10:1995;1709-1715.
87. Martin K., Trouche D., Hagemeier C., Sørensen T.S., La Thangue N.B., Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 375:1995;691-694.
88. Mayo L.D., Turchi J.J., Berberich S.J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57:1997;5013-5316.
89. McMasters K.M., Montes de Oca Luna R., Pena J.R., Lozano G. Mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 13:1996;1731-1736.
90. Midgley C.A., Lane D.P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1997;1179-1189.
91. Miyashta T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
92. Momand J., Zambetti G.P. Mdm-2: "Big Brother" of p53. J. Cell. Biochem. 64:1997;343-352.
93. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
94. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26:1998;3453-3459.
95. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206.
96. Mosner J., Deppert W. p53 and mdm2 are expressed independently during cellular proliferation. Oncogene. 9:1994;3321-3328.
97. Mummenbrauer T., Janus F., Muller B., Wiesmuller L., Deppert W., Grosse F. p53 protein exhibits 3′-to-5′ exonuclease activity. Cell. 85:1996;1089-1099.
98. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
99. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
100. Olson D.C., Marechal V., Momand J., Chen J., Romacki C., Levine A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene. 8:1993;2353-2360.
101. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I., Ikawa Y., Nimura Y., Nakagawara A., Obinata M., Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:1998;839-843.
102. Picksley S.M., Vojtesek B., Sparks A., Lane D.P. Immunochemical analysis of the interaction of p53 with MDM2 - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 9:1994;2523-2529.
103. Piette J., Neel H., Maréchal V. Mdm2: keeping p53 under control. Oncogene. 15:1997;1001-1010.
104. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
105. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 95:1998;95-98.
106. Qin X.Q., Chittenden T., Livingston D.M., Kaelin W.G.J. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6:1992;953-964.
107. Raycroft L., Wu H., Lozano G. Transcriptional activation by the wild-type but not transforming mutants of the p53 anti-oncogene. Science. 249:1990;1049-1051.
108. Reinke V., Bortner D.M., Amelse L.L., Lundgren K., Rosenberg M.P., Finlay C.A., Lozano G. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 10:1999;147-154.
109. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immonodeficiency virus rev protein. EMBO J. 17:1998;554-564.
110. Rovinski B., Munroe D., Peacock J., Mowat M., Bernstein A., Benchimol S. Deletion of 5′-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol. Cell. Biol. 7:1987;847-853.
111. Shieh S.-Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
112. Shieh S.Y., Taya Y., Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 18:1999;1815-1823.
113. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
114. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.
115. Stommel J.M., Marchenko N.D., Jimenez G.S., Moll U.M., Hope T.J., Wahl G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1999;1660-1672.
116. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:1998;5001-5014.
117. Tanimura S., Ohtsuka S., Mitsui K., Shirouzu K., Yoshimura A., Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:1999;5-9.
118. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA. 96:1999;3077-3080.
119. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA. 96:1999;6937-6941.
120. Teoh G., Urashima M., Ogata A., Chauhan D., DeCaprio J.A., Treon S.P., Schlossman R.L., Anderson K.C. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 90:1997;1982-1992.
121. Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1999;1805-1814.
122. Unger T., Sionov R.V., Moallem E., Yee C.L., Howley P.M., Oren M., Haupt Y. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene. 18:1999;3205-3212.
123. Wadgaonkar R., Collins T. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. 274:1999;13 760-13 767.
124. Wang Y., Schwedes J.F., Parks D., Mann K., Tegtmeyer P. Interaction of p53 with its consensus DNA-binding site. Mol. Cell. Biol. 15:1995;2157-2165.
125. Wasylyk C., Salvi R., Argentini M., Dureuil C., Delumeau I., Abecassis J., Debussche L., Wasylyk B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene. 18:1999;1921-1934.
126. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1:1999;20-26.
127. Wu X., Levine A.J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;3602-3606.
128. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1136.
129. Xiao Z.X., Chen J., Levine A.J., Modjtahedi N., Xing J., Sellers W.R., Livingston D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 375:1995;694-698.
130. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing and dominant-negative activities. Mol. Cell. 2:1998;305-316.
131. Zeng X., Chen L., Jost C.A., Maya R., Keller D., Wang X., Kaelin W.G.J., Oren M., Chen J., Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19:1999;3257-3266.
132. Zhang Y., Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell. 3:1999;579-591.
133. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
134. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:1998;2424-2433.